InvestorTalk Alert: Brent Willis from Voyageur Pharmaceuticals Ltd. to host on Wednesday, May 29, 2024

written by InvestorNews | May 28, 2024

InvestorNews is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Wednesday, May 29th, at 9 AM EST, featuring Brent Willis, the President, CEO, and Director of Voyageur Pharmaceuticals Ltd. (TSXV: VM). To participate in this engaging discussion, please click here

Currently, Voyageur Pharmaceuticals holds 138,881,576 shares outstanding and has a market capitalization of CAD$6,249,671.

In preparation for tomorrow’s InvestorTalk, here are the three most recent news releases from Voyageur Pharmaceuticals for your review:

  • May 28, 2024 — Voyageur Pharmaceuticals Ltd Secures USD $1.9 Million Sales Contract for SmoothX 2% Barium Contrast — click here
  • April 3, 2024 — Voyageur Pharmaceuticals Ltd Grants Deferred Share Units Compensation to Independent Directors — click here
  • March 26, 2024 — Voyageur Pharmaceuticals Files Audited Annual Financial Statements and Grants Stock Options — click here

5-Data Points from Voyageur’s most recent news release on May 28, 2024, titled, Voyageur Pharmaceuticals Ltd Secures USD $1.9 Million Sales Contract for SmoothX 2% Barium Contrast:

  • Sales Contract Value: Voyageur Pharmaceuticals has secured a sales contract valued at USD $1.9 million (CAD $2.6 million) for the first three years of commercialization of their SmoothX 2% barium contrast medium.
  • International Expansion: This contract marks the company’s first international distribution agreement, targeting the radiology product market in Latin America and involving marketing and sales rights in two countries.
  • Expansion into U.S. Market: Voyageur plans to expand into the U.S. market, leveraging regulatory approvals and successes in other countries to introduce its innovative imaging products.
  • Future Product Line: Voyageur has four additional barium sulfate contrast medium products at late stages of development, which include high-density and low-density solutions for various gastrointestinal radiographic examinations.
  • Corporate Strategy and Commitment: Voyageur is planning to expand into the U.S. market and aims to become a vertically integrated, carbon-neutral company in the radiology contrast media drug market, emphasizing sustainability and cost efficiency.

(05.28.2024 at 12:00 PM EST, Source)

For more information on Voyageur Pharmaceuticals Ltd., click here.

For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.